HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kathy D Miller Selected Research

N- hydroxy- 2- (((4'- methoxyphenyl)sulfonyl)benzylamino)- 3- methylbutanamide

1/2004Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kathy D Miller Research Topics

Disease

78Breast Neoplasms (Breast Cancer)
10/2022 - 10/2002
67Neoplasms (Cancer)
02/2022 - 11/2002
14Triple Negative Breast Neoplasms
01/2022 - 12/2014
7Neoplasm Metastasis (Metastasis)
12/2020 - 06/2003
5Hypertension (High Blood Pressure)
01/2018 - 02/2005
4Fatigue
10/2022 - 05/2014
4Ovarian Neoplasms (Ovarian Cancer)
12/2020 - 12/2007
3Heart Failure
01/2019 - 01/2017
3Exanthema (Rash)
01/2018 - 03/2004
3Peripheral Nervous System Diseases (PNS Diseases)
01/2017 - 11/2015
2Neutropenia
10/2022 - 01/2021
2Carcinogenesis
10/2021 - 06/2003
2Circulating Neoplastic Cells
01/2020 - 12/2018
2Residual Neoplasm
01/2020 - 01/2020
2Disease Progression
01/2018 - 01/2018
2Prostatic Neoplasms (Prostate Cancer)
12/2011 - 10/2006
1Mouth Neoplasms (Oral Cancer)
10/2022
1Lymphedema (Milroy Disease)
12/2021
1Carcinoma (Carcinomatosis)
12/2020

Drug/Important Bio-Agent (IBA)

16Bevacizumab (Avastin)FDA Link
02/2022 - 02/2003
13Estrogen ReceptorsIBA
01/2022 - 06/2003
12ErbB Receptors (EGF Receptor)IBA
10/2022 - 01/2004
10Hormones (Hormone)IBA
10/2022 - 10/2006
10taxaneIBA
01/2019 - 02/2005
10Biomarkers (Surrogate Marker)IBA
12/2018 - 03/2004
9Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 03/2004
9AnthracyclinesIBA
01/2019 - 02/2005
9EnzymesIBA
01/2017 - 11/2004
9Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2013 - 10/2003
8Paclitaxel (Taxol)FDA LinkGeneric
12/2018 - 02/2003
7Carbon-11IBA
11/2009 - 11/2006
6Pharmaceutical PreparationsIBA
10/2021 - 10/2002
6DNA (Deoxyribonucleic Acid)IBA
01/2019 - 12/2007
6Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2018 - 03/2004
5Capecitabine (Xeloda)FDA Link
01/2022 - 11/2004
5Estrogens (Estrogen)FDA Link
01/2019 - 06/2003
4Aromatase InhibitorsIBA
10/2021 - 06/2013
4Proteins (Proteins, Gene)FDA Link
10/2021 - 10/2002
4Trastuzumab (Herceptin)FDA Link
10/2021 - 04/2008
4human ERBB2 proteinIBA
10/2021 - 09/2012
4TamoxifenFDA LinkGeneric
01/2019 - 06/2003
4Biological ProductsIBA
01/2018 - 10/2002
4Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2006 - 05/2005
4Matrix Metalloproteinase InhibitorsIBA
03/2004 - 10/2002
4Matrix Metalloproteinases (MMPs)IBA
12/2003 - 10/2002
3palbociclibIBA
10/2022 - 01/2021
3CytokinesIBA
02/2022 - 06/2003
3exemestane (Aromasin)FDA Link
10/2021 - 06/2013
3entinostat (MS 275)IBA
10/2021 - 06/2013
3Histone Deacetylase InhibitorsIBA
10/2021 - 06/2013
3RNA (Ribonucleic Acid)IBA
01/2019 - 06/2007
3Aromatase (CYP19)IBA
12/2010 - 01/2007
3Antineoplastic Agents (Antineoplastics)IBA
03/2010 - 11/2004
3Docetaxel (Taxotere)FDA Link
06/2007 - 01/2005
2Fatty Acid Synthases (Fatty Acid Synthase)IBA
11/2021 - 01/2021
2Progesterone Receptors (Progesterone Receptor)IBA
12/2020 - 03/2013
2Circulating Tumor DNAIBA
01/2020 - 01/2017
2gancotamabIBA
10/2018 - 08/2017
2Phosphotransferases (Kinase)IBA
01/2018 - 01/2006
2Fluorouracil (Carac)FDA LinkGeneric
08/2017 - 11/2004
2Acetates (Acetic Acid Esters)FDA Link
01/2017 - 04/2008
2Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric
11/2014 - 08/2008
2Ado-Trastuzumab EmtansineIBA
05/2014 - 09/2012
2sulfamic acid (ammonium sulfamate)IBA
07/2012 - 11/2009
2Steryl-Sulfatase (Steroid Sulfatase)IBA
07/2012 - 11/2009
2Oxygen (Dioxygen)IBA
12/2011 - 06/2011
2Monoclonal AntibodiesIBA
12/2011 - 02/2005
2Celecoxib (Celebrex)FDA Link
09/2011 - 11/2009
2EphA2 ReceptorIBA
06/2011 - 06/2003
2vandetanib (ZD6474)IBA
06/2011 - 05/2005
2Angiogenesis InhibitorsIBA
12/2008 - 10/2007
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
10/2008 - 05/2005
21,2,3,4-tetrahydroisoquinolineIBA
10/2008 - 10/2007
2Sunitinib (Sutent)FDA Link
04/2008 - 10/2005
2Tyrosine Kinase InhibitorsIBA
04/2008 - 05/2005
22-MethoxyestradiolIBA
02/2007 - 08/2005
2Fluorine-18IBA
11/2006 - 11/2004
2Transcription Factors (Transcription Factor)IBA
10/2006 - 06/2003
2NF-kappa B (NF-kB)IBA
10/2006 - 06/2003
2Interleukin-1alpha (Interleukin 1 alpha)IBA
12/2003 - 10/2003
1NivolumabIBA
01/2022
1IpilimumabIBA
01/2022
1Cyclin-Dependent Kinase 4IBA
01/2022
1gedatolisibIBA
01/2022
1cofetuzumab pelidotinIBA
01/2022
1PlatinumIBA
10/2021
1CI 22IBA
10/2021
1AmanitinsIBA
10/2021
1Immune Checkpoint InhibitorsIBA
10/2021
1Cisplatin (Platino)FDA LinkGeneric
03/2021
1rucaparibIBA
03/2021
1Proton Pump InhibitorsIBA
01/2021
1N- benzhydryl- 5- (2- (methylamino)propanamido)- 3- (3- methylbutanoyl)- 6- oxodecahydropyrrolo(1,2- a)(1,5)diazocine- 8- carboxamideIBA
01/2021
1ProgesteroneFDA LinkGeneric
12/2020
1A-factor (Streptomyces)IBA
12/2020

Therapy/Procedure

43Therapeutics
10/2022 - 01/2003
19Drug Therapy (Chemotherapy)
01/2022 - 10/2003
6Adjuvant Chemotherapy
02/2022 - 02/2008
6Neoadjuvant Therapy
01/2022 - 01/2017
1Immunotherapy
10/2021